Skip to main content
NASDAQ:VRTX

Vertex Pharmaceuticals Stock Forecast, Price & News

$214.35
+1.67 (+0.79 %)
(As of 05/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$212.33
$215.02
50-Day Range
$210.28
$221.10
52-Week Range
$202.57
$306.08
Volume1.08 million shs
Average Volume1.91 million shs
Market Capitalization$55.49 billion
P/E Ratio27.06
Dividend YieldN/A
Beta0.79
30 days | 90 days | 365 days | Advanced Chart
Receive VRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.


Vertex Pharmaceuticals logo

About Vertex Pharmaceuticals

Vertex Pharmaceuticals, Inc. is a global biotechnology company. It engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. The firm focuses on development and commercializing therapies for the treatment of cystic fibrosis, infectious diseases including viral infections such as influenza and bacterial infections, autoimmune diseases such as rheumatoid arthritis, cancer, inflammatory bowel disease and neurological disorders including pain and multiple sclerosis. The company was founded by Joshua S. Boger in 1989 and is headquartered in Boston, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VRTX
CUSIP92532F10
Phone(617) 341-6100
Employees3,400
Year Founded1989

Sales & Book Value

Annual Sales$4.16 billion
Cash Flow$4.63 per share
Book Value$23.66 per share

Profitability

Net Income$1.18 billion

Debt

Price-To-Earnings

Miscellaneous

Market Cap$55.49 billion
Next Earnings Date7/29/2021 (Estimated)
OptionableOptionable

Social Links


MarketRank

Overall MarketRank

2.03 out of 5 stars

Medical Sector

46th out of 2,038 stocks

Pharmaceutical Preparations Industry

19th out of 769 stocks

Analyst Opinion: 3.4Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions

Is Vertex Pharmaceuticals a buy right now?

21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last twelve months. There are currently 4 hold ratings, 16 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Vertex Pharmaceuticals stock.
View analyst ratings for Vertex Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Vertex Pharmaceuticals?

Wall Street analysts have given Vertex Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Vertex Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Vertex Pharmaceuticals' next earnings date?

Vertex Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, July 29th 2021.
View our earnings forecast for Vertex Pharmaceuticals
.

How were Vertex Pharmaceuticals' earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its quarterly earnings data on Thursday, April, 29th. The pharmaceutical company reported $2.98 EPS for the quarter, topping the consensus estimate of $2.38 by $0.60. The pharmaceutical company earned $1.72 billion during the quarter, compared to the consensus estimate of $1.66 billion. Vertex Pharmaceuticals had a trailing twelve-month return on equity of 28.55% and a net margin of 38.51%.
View Vertex Pharmaceuticals' earnings history
.

How has Vertex Pharmaceuticals' stock price been impacted by Coronavirus?

Vertex Pharmaceuticals' stock was trading at $220.34 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, VRTX shares have decreased by 2.7% and is now trading at $214.35.
View which stocks have been most impacted by COVID-19
.

How will Vertex Pharmaceuticals' stock buyback program work?

Vertex Pharmaceuticals announced that its board has authorized a stock repurchase plan on Wednesday, July 31st 2019, which allows the company to repurchase $500,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to purchase up to 1.2% of its shares through open market purchases. Shares repurchase plans are often an indication that the company's leadership believes its shares are undervalued.

What guidance has Vertex Pharmaceuticals issued on next quarter's earnings?

Vertex Pharmaceuticals updated its FY 2021 earnings guidance on Thursday, May, 13th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $6.70 billion-$6.90 billion, compared to the consensus revenue estimate of $6.95 billion.

What price target have analysts set for VRTX?

21 Wall Street analysts have issued 1-year target prices for Vertex Pharmaceuticals' stock. Their forecasts range from $250.00 to $347.00. On average, they expect Vertex Pharmaceuticals' share price to reach $293.47 in the next twelve months. This suggests a possible upside of 36.9% from the stock's current price.
View analysts' price targets for Vertex Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Vertex Pharmaceuticals' key executives?

Vertex Pharmaceuticals' management team includes the following people:
  • Reshma Kewalramani, President, Chief Executive Officer & Director
  • Charles F. Wagner, Chief Financial Officer & Executive Vice President
  • David Matthew Altshuler, Chief Scientific Officer & EVP-Global Research
  • Mike Tirozzi, Senior VP, Chief Information & Data Officer
  • Carmen Bozic, Chief Medical Officer & EVP-Medical Affairs

What is Reshma Kewalramani's approval rating as Vertex Pharmaceuticals' CEO?

31 employees have rated Vertex Pharmaceuticals CEO Reshma Kewalramani on Glassdoor.com. Reshma Kewalramani has an approval rating of 76% among Vertex Pharmaceuticals' employees.

Who are some of Vertex Pharmaceuticals' key competitors?

What other stocks do shareholders of Vertex Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Companhia de Saneamento Básico do Estado de São Paulo - SABESP (SBS), Alibaba Group (BABA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Micron Technology (MU), salesforce.com (CRM), Netflix (NFLX), Intel (INTC) and PayPal (PYPL).

What is Vertex Pharmaceuticals' stock symbol?

Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."

Who are Vertex Pharmaceuticals' major shareholders?

Vertex Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (9.37%), Alliancebernstein L.P. (3.04%), Clearbridge Investments LLC (2.13%), Geode Capital Management LLC (1.52%), Northern Trust Corp (1.15%) and Massachusetts Financial Services Co. MA (1.10%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, Bastiano Sanna, Bruce I Sachs, Charles F Wagner Jr, David Altshuler, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Ourania Tatsis, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle, William D Young and Yuchun Lee.
View institutional ownership trends for Vertex Pharmaceuticals
.

Which major investors are selling Vertex Pharmaceuticals stock?

VRTX stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Assenagon Asset Management S.A., Prudential Financial Inc., Mirae Asset Global Investments Co. Ltd., Bank of New York Mellon Corp, Lord Abbett & CO. LLC, Franklin Resources Inc., and Robeco Institutional Asset Management B.V.. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, Bastiano Sanna, Charles F Wagner Jr, Jeffrey M Leiden, Michael Parini, Paul M Silva, Sangeeta N Bhatia, and Stuart A Arbuckle.
View insider buying and selling activity for Vertex Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Vertex Pharmaceuticals stock?

VRTX stock was acquired by a variety of institutional investors in the last quarter, including Clearbridge Investments LLC, ARK Investment Management LLC, Mayflower Financial Advisors LLC, Manning & Napier Group LLC, Bank of Montreal Can, Massachusetts Financial Services Co. MA, Retirement Systems of Alabama, and Panagora Asset Management Inc..
View insider buying and selling activity for Vertex Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Vertex Pharmaceuticals?

Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vertex Pharmaceuticals' stock price today?

One share of VRTX stock can currently be purchased for approximately $214.35.

How much money does Vertex Pharmaceuticals make?

Vertex Pharmaceuticals has a market capitalization of $55.49 billion and generates $4.16 billion in revenue each year. The pharmaceutical company earns $1.18 billion in net income (profit) each year or $4.29 on an earnings per share basis.

How many employees does Vertex Pharmaceuticals have?

Vertex Pharmaceuticals employs 3,400 workers across the globe.

Does Vertex Pharmaceuticals have any subsidiaries?

The following companies are subsidiares of Vertex Pharmaceuticals: Semma Therapeutics.

When was Vertex Pharmaceuticals founded?

Vertex Pharmaceuticals was founded in 1989.

What is Vertex Pharmaceuticals' official website?

The official website for Vertex Pharmaceuticals is www.vrtx.com.

Where are Vertex Pharmaceuticals' headquarters?

Vertex Pharmaceuticals is headquartered at 50 NORTHERN AVENUE, BOSTON MA, 02210.

How can I contact Vertex Pharmaceuticals?

Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at (617) 341-6100 or via email at [email protected]


This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.